Last updated on November 2017

A Randomized, Double Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects with Ulcerative Colitis


Brief description of study

A Randomized, Double Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects with Ulcerative Colitis

Detailed Study Description

The purpose of the study is to determine the effect of Vedolizumab IV compared to adalimumab SC on achieving clinical remission in patients with Ulcerative Colitis, at Week 52.

Clinical Study Identifier: TX5545

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Crystal Beaber, MA, CCRC

Gastroenterology Associates of Tidewater
Chesapeake, VA USA
  Connect »